In addition, it has been reported that increased tumor-infiltrating DCs and upregulated their CD86 expression in vivo lead to increased tumor-infiltrating CD8+ T cells and enhanced PD-L1 and MHC class I expression on tumor cells (35). The gene discussed is CD8A; the disease is neoplasm.